 | | Vol. 10.46 – 24 November, 2021 |
| |
|
|
| Researchers showed that loss of ABHD5 promoted c-Met activation to sustain colorectal cancer stemness in a non-canonical manner.
[Nature Communications] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists assessed the role of the sulfiredoxin-peroxiredoxin redox system and mitochondrial oxidative phosphorylation in maintaining the stemness and survival of colon CSCs.
[Redox Biology] |
|
|
|
| The mechanism by which autophagy affects the self-renewal of CSCs remains unclear. Researchers investigated whether autophagy activation contributed to CSC properties of head and neck squamous cell carcinoma.
[Oncogene] |
|
|
|
| Scientists found that progestin resistance of endometrial CSCs could be improved or reversed by using in vitro fertilization (IVF)-generated embryonic sac-derived fluid containing the embryonic microenvironment.
[Cancer Letters] |
|
|
|
| The authors investigated whether transmembrane serine protease 4 (TMPRSS4) confered cancer stem–like properties to prostate cancer cells and characterized the underlying mechanisms.
[Journal of Experimental & Clinical Cancer Research] |
|
|
|
| Researchers tested the hypothesis that metabolic stress induced breast cancer stem-like cell phenotype in triple-negative breast cancer.
[British Journal of Cancer] |
|
|
|
| Circular RNA (circRNA) is a unique sort of non-coding RNAs and widely participate in the modulation of cancer progression. Investigators identified the critical function of circRNA circPIP5K1A in stemness of osteosarcoma cells.
[Journal of Translational Medicine] |
|
|
|
| Scientists examined the regulatory effects of tumor necrosis factor receptor-associated factor-binding protein domain (ZRANB1) on the maintenance of CSC properties and tumor growth in colorectal cancer.
[Cellular Signalling] |
|
|
|
| Secretome analysis was performed in pancreatic CSC-enriched spheres and controlled adherent cells for biomarker discovery.
[BMC Cancer] |
|  |
|
|
|
| Scientists summarize current clinical trials, which assessed the safety and efficacy of breast cancer stem cells-related therapies.
[Journal of Experimental & Clinical Cancer Research] |
|
|
|
|
| Biosplice Therapeutics, Inc. announced the dosing of the first subject in a Phase Ib, open-label, multicenter, dose-escalation, dose expansion clinical trial of cirtuvivint in subjects with advanced solid tumors.
[Biosplice Therapeutics, Inc.] |
|
|
|
|
| December 1 – 10, 2021
Virtual |
|
|
|
|
|
| Fred Hutchinson Cancer Research Center – Seattle, Washington, United States |
|
|
|
| Weill Cornell Medical College – New York, New York, United States |
|
|
|
| | Oregon Health & Science University – Portland, Oregon, United States |
|
|
|
| | St. Jude Children’s Research Hospital – Memphis, Tennessee, United States |
|
|
|
| The University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
